Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alex Shimmings

Alexandra has more than 20 years' experience covering pharmaceutical and biotech R&D. An early interest in medicine, and a dawning realization that being a doctor was not for her, led to a degree in Biochemistry and Microbiology at the University of Leeds, and a move to London to pursue a career in medical journalism. Now Scrip's Managing Editor, Alex has held a variety of roles on the publication since starting as a science reporter in 1998. She instigated some of Scrip's signature features, such as the Pipeline Watch and New Active Substance lists, and also casts an editorial eye over the annual Scrip Awards. Alex's main work interests lie in novel drugs and pharmaceutical and biotech R&D, and she also enjoys medical history and current affairs.
Advertisement
Set Alert for Articles By Alex Shimmings

Latest From Alex Shimmings

AstraZeneca Rejig Brings Baselga On Board

A reorganization at the top of the UK firm brings with it controversial scientist Jose Baselga.

Companies Appointments

Scrip’s Top Five Stories Of 2018

A look back at the Scrip stories that piqued the most interest for our readers in 2018. 

Companies Commercial

Supernus’ ADHD Drug Hits Phase III Endpoint As Filing Beckons

The first of two Phase III trials of Supernus’ ADHD candidate has hit its endpoints in adolescents. The second is due to report in early 2019, setting the stage for regulatory filings.

Clinical Trials Research & Development

SOLO-3 Adds To AZ/MSD’s Lynparza’s Ovarian Cancer Success Tally But Impact Minimal

Companies plan to discuss SOLO-3 data with the US FDA after Lynparza shows a benefit in third-line ovarian cancer, but commercial impact will be slight.

Clinical Trials Cancer

Vertex Pain Product VX-150 Comes Out Of The Shadows

Solid Phase II efficacy data for Vertex’s pain product have brought it blinking into the light. Analysts are hoping it will lead to an additional revenue stream for Vertex behind its all-conquering cystic fibrosis franchise.

Clinical Trials Research & Development

Novartis Pruned Pipeline Producing Attractive Respiratory And Neurology Fruits

Novartis executives highlighted their stars from its refined pipeline during the company’s first R&D day since Vas Narasimhan took the helm and after a cull that reduced the firm’s development portfolio by 20%.

Companies Research & Development
See All
Advertisement
UsernamePublicRestriction

Register